About   Help   FAQ
Mammalian Phenotype Ontology Annotations
Query Results - Summary
Symbol
Name
ID
Fto
fat mass and obesity associated
MGI:1347093
62 phenotypes from 10 alleles in 9 genetic backgrounds
Export: Excel File
Allelic Composition
Genetic Background
Annotated Term Reference
FtoGt(RRZ624)Byg/FtoGt(RRZ624)Byg
involves: 129P2/OlaHsd
normal growth/size/body region phenotype J:166984
FtoI367F/Fto+
involves: C3H/HeH * C57BL/6J
abnormal metabolism J:152163
decreased body weight J:152163
decreased percent body fat/body weight J:152163
decreased total body fat amount J:152163
increased carbon dioxide production J:152163
increased oxygen consumption J:152163
increased respiratory quotient J:152163
FtoI367F/FtoI367F
involves: C3H/HeH * C57BL/6J
abnormal metabolism J:152163
abnormal urine catecholamine level J:152163
decreased body weight J:152163
decreased carbon dioxide production J:152163
decreased circulating insulin level J:152163
decreased percent body fat/body weight J:152163
decreased total body fat amount J:152163
increased carbon dioxide production J:152163
increased circulating cholesterol level J:152163
increased circulating glucagon level J:152163
increased circulating glucose level J:152163
increased circulating HDL cholesterol level J:152163
increased circulating leptin level J:152163
increased circulating triglyceride level J:152163
increased lean body mass J:152163
increased oxygen consumption J:152163
increased respiratory quotient J:152163
Ftotm1.1Pzg/Ftotm1.1Pzg
Tg(Nes-cre)1Kln/0
involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6 * SJL
abnormal carbon dioxide production J:166984
abnormal eating behavior J:166984
abnormal oxygen consumption J:166984
decreased body length J:166984
decreased bone mineral density J:166984
decreased circulating insulin-like growth factor I level J:166984
decreased lean body mass J:166984
postnatal growth retardation J:166984
Ftotm1.1Rdc/Ftotm1.1Rdc
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
decreased body weight J:194922
decreased food intake J:194922
normal homeostasis/metabolism phenotype J:194922
Ftotm1.1Rdc/Ftotm1.1Rdc
Ndor1Tg(UBC-cre/ERT2)1Ejb/0
involves: 129S/SvEv * 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL
decreased body weight J:194922
decreased carbon dioxide production J:194922
decreased lean body mass J:194922
decreased respiratory quotient J:194922
normal homeostasis/metabolism phenotype J:194922
increased total body fat amount J:194922
premature death J:194922
Ftotm1.2Pzg/Ftotm1.2Pzg
involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6
abnormal carbon dioxide production J:166984
abnormal eating behavior J:166984
abnormal oxygen consumption J:166984
cachexia J:166984
decreased body length J:166984
decreased body weight J:166984
decreased bone mineral density J:166984
decreased circulating insulin-like growth factor I level J:166984
decreased lean body mass J:166984
dermatitis J:166984
increased susceptibility to diet-induced obesity J:166984
increased total body fat amount J:166984
postnatal growth retardation J:166984
postnatal lethality, incomplete penetrance J:166984
Ftotm1.2Rdc/Ftotm1.2Rdc
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * C57BL/6J * SJL
decreased body weight J:194922
decreased lean body mass J:194922
decreased respiratory quotient J:194922
normal homeostasis/metabolism phenotype J:194922
improved glucose tolerance J:194922
increased food intake J:194922
increased oxygen consumption J:194922
preweaning lethality, incomplete penetrance J:194922
Ftotm1.3Pzg/Ftotm1.3Pzg
involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6
abnormal carbon dioxide production J:166984
abnormal eating behavior J:166984
abnormal oxygen consumption J:166984
cachexia J:166984
decreased body length J:166984
decreased body weight J:166984
decreased bone mineral density J:166984
decreased circulating insulin-like growth factor I level J:166984
decreased lean body mass J:166984
dermatitis J:166984
increased susceptibility to diet-induced obesity J:166984
increased total body fat amount J:166984
postnatal growth retardation J:166984
postnatal lethality, incomplete penetrance J:166984
Ftotm1a(EUCOMM)Wtsi/Ftotm1a(EUCOMM)Wtsi
B6JTyr;B6N-Ftotm1a(EUCOMM)Wtsi/Wtsi
decreased body weight J:165965
decreased circulating alanine transaminase level J:175295
decreased circulating aspartate transaminase level J:175295
decreased circulating iron level J:175295
decreased circulating LDL cholesterol level J:175295
decreased lactate dehydrogenase level J:175295
hyperactivity J:175295
Ftotm1Urt/Fto+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
decreased susceptibility to diet-induced obesity J:147471
Ftotm1Urt/Ftotm1Urt
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
abnormal circulating hormone level J:147471
decreased body length J:147471
decreased body weight J:147471
decreased circulating leptin level J:147471
decreased gonadal fat pad weight J:147471
decreased lean body mass J:147471
decreased susceptibility to diet-induced obesity J:147471
decreased total body fat amount J:147471
decreased white fat cell size J:147471
hypoactivity J:147471
increased basal metabolism J:147471
increased carbon dioxide production J:147471
increased circulating adrenaline level J:147471
increased energy expenditure J:147471
increased oxygen consumption J:147471
polyphagia J:147471
postnatal growth retardation J:147471
postnatal lethality, incomplete penetrance J:147471
Gt(ROSA)26Sortm1.1(CAG-Fto)Rdc/Gt(ROSA)26Sor+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * SJL
abnormal circulating lipid level J:166829
abnormal hormone level J:166829
decreased adiponectin level J:166829
decreased circulating LDL cholesterol level J:166829
increased abdominal fat pad weight J:166829
increased body weight J:166829
increased circulating free fatty acid level J:166829
increased circulating HDL cholesterol level J:166829
increased circulating leptin level J:166829
increased circulating triglyceride level J:166829
increased food intake J:166829
increased lean body mass J:166829
increased susceptibility to diet-induced obesity J:166829
increased total body fat amount J:166829
Gt(ROSA)26Sortm1.1(CAG-Fto)Rdc/Gt(ROSA)26Sortm1.1(CAG-Fto)Rdc
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * SJL
abnormal circulating lipid level J:166829
abnormal hormone level J:166829
decreased adiponectin level J:166829
decreased circulating LDL cholesterol level J:166829
decreased circulating leptin level J:166829
impaired glucose tolerance J:166829
increased abdominal fat pad weight J:166829
increased body weight J:166829
increased circulating free fatty acid level J:166829
increased circulating HDL cholesterol level J:166829
increased circulating insulin level J:166829
increased circulating triglyceride level J:166829
increased energy expenditure J:166829
increased food intake J:166829
increased lean body mass J:166829
increased susceptibility to diet-induced obesity J:166829
increased total body fat amount J:166829

Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer & Copyright Notice
Send questions and comments to User Support.
last database update
11/05/2019
MGI 6.14
The Jackson Laboratory